10 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Rekah Pharmaceutical Industry Ltd. (REKA) operates in the Health Care industry and is headquartered in חולון, Israel with about 390 employees. Its market capitalization is roughly ₪118 million. In the fiscal year ended 2025-12-31, REKA reported ₪301M in revenue and (₪18M) in net income.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products.
Interactive charts & full statements → Open the REKA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2021-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | ₪301M | ₪322M | — | — | ₪196M | ₪208M | ₪208M | ₪218M |
| Gross Profit | ₪70M | ₪72M | — | — | ₪61M | ₪67M | ₪68M | ₪68M |
| Net Income | (₪18M) | ₪6M | — | ₪0M | ₪1M | ₪7M | (₪23M) | (₪11M) |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Total Revenue | ₪79M | ₪77M | ₪75M | ₪76M | ₪76M |
| Gross Profit | ₪17M | ₪16M | ₪17M | ₪20M | ₪19M |
| Operating Income (EBIT) | (₪1M) | (₪2M) | (₪2M) | ₪0M | ₪0M |
| Net Income | (₪3M) | (₪6M) | (₪5M) | (₪2M) | (₪2M) |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2021-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|
| Dividends Paid | — | ₪0M | ₪0M | — | — | — | — | — |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2021-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₪424M | ₪447M | ₪485M | — | ₪367M | ₪300M | ₪295M | ₪323M |
| Cash & Cash Equivalents | ₪4M | ₪7M | ₪19M | ₪19M | ₪26M | ₪32M | ₪25M | ₪32M |
| Total Liabilities | ₪279M | ₪285M | — | — | ₪212M | ₪150M | ₪150M | ₪217M |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive REKA viewer.
This page in other languages: עברית
About TickerBase · Data methodology & sources · Privacy · Terms